Anti COVID-19 drug authorized in US for those uneligible for vaccination
The FDA authorized AstraZeneca's Evusheld, a COVID-19 treatment combining tixagevimab and cilgavimab, for unvaccinated individuals aged 12+ with medical constraints. It's not a vaccine substitute, effective for six months pre-exposure, and reduces COVID-19 risk by 77%. Side effects include allergic reactions and fatigue.
Reference News
Anti COVID-19 drug authorized in US for those uneligible for vaccination
The FDA authorized AstraZeneca's Evusheld, a COVID-19 treatment combining tixagevimab and cilgavimab, for unvaccinated individuals aged 12+ with medical constraints. It's not a vaccine substitute, effective for six months pre-exposure, and reduces COVID-19 risk by 77%. Side effects include allergic reactions and fatigue.